Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Communication Strategies. Case Studies. Applied Knowledge.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Sign in to register as a Member Not a member? Join Today!
Register as a Nonmember
Friday, 18 February 2022 (9:00 AM - 4:00 PM) Central European Time
On 31 January 2022, the new Regulation EU No 536/2014 of the European Parliament and of the council on clinical trials on medicinal products for human use, will likely come into force and change the procedure for assessment and approval of multinational clinical trial authorization applications. As a result, a single authorization procedure for clinical trials will be introduced that will be performed electronically via a new EU portal.
The regulation will ensure that, no matter where a clinical trial is being performed, the fundamental rules for the protection of subjects are applied. It therefore includes rules for clinical trials which are conducted outside the EU but referred to in a clinical trial application within the EU. For such trials, the rules call for compliance with regulatory requirements at least equivalent to those in the EU clinical trials regulation, including rules on transparency.
During this workshop, Adriaan Fruijtier, of CATS Consultants will discuss important changes regarding the protection of subjects and provide a detailed overview of the new procedure. Additionally, he will explain how the new regulation will affect the way the conduct of a clinical trial is managed after approval has been granted. New provisions for public access to an EU clinical trials database will enforce disclosure of clinical trials data and information.
Before 18 January 2022: Member € 555 | Nonmember € 650
After 18 January 2022: Member € 650 | Nonmember € 770
Upon completion of this workshop, participants will be able to:
Adriaan Fruijtier, CATS Consultants
Adriaan Fruijtier has graduated as a pharmacist at the University of Utrecht, The Netherlands. Until March 2004 was head of the oncology group within global regulatory affairs at Bayer AG, Wuppertal, Germany, and Bayer Corporation, West Haven, CT, USA. Between 2001 and 2003 he was director of regulatory affairs at Micromet AG, a biotech company in Munich, Germany. Prior to joining Micromet, he worked four years as a project manager for oncology projects at the European Medicines Agency (EMA) in London, UK.
He joined EMA from Novartis AG, Basel, Switzerland, where he was regulatory affairs project manager in the oncology group in 1996 and 1997. Before 1996, he was head of drug regulatory affairs for six years at Ciba-Geigy in the Netherlands and has worked as a manager of regulatory affairs at Glaxo, also in the Netherlands.
RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation.
All cancellation requests must be submitted in writing via our online cancellation form. RAPS is unable to accept cancellations by phone. Please specify the name of the person registered and event title.
Substitutions may be accepted with written approval from RAPS and must be submitted to firstname.lastname@example.org.